Jishi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jishi Wang has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
Qin Fang
Department of Pharmacy, Affiliated Hospital of Guizhou Medical University, Guiyang, China
43 shared publicationsDan Ma
Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou Province Institute of Hematology, Guizhou Province Laboratory of Hematopoietic Stem Cell Transplantation Centre, Guiyang, China
34 shared publicationsTianzhuo Zhang
Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China
17 shared publicationsChengyun Pan
Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou Province Institute of Hematology, Guizhou Province Laboratory of Hematopoietic Stem Cell Transplantation Centre, Guiyang, China
16 shared publicationsTingting Lu
Center for Clinical Laboratories, Affiliated Hospital of Guizhou Medical University, Guiyang, China
16 shared publicationsPing Liu
Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
15 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
EXOSC4 as a novel regulator of neddylation in acute myeloid leukemia
Acute myeloid leukaemia (AML) is a common haematological malignancy with an unsatisfactory prognosis despite recent therapeutic advances. Neddylation and ferroptosis have been implicated in the regulation of malignant cell proliferation, survival and therapy response. However, the relationship between neddylation-related dysregulation and ferroptosis-associated pathways in AML remains poorly understood. Transcriptomic data from TCGA-AML and GTEx normal controls were integrated for differential expression and functional enrichment analyses. Prognostic neddylation-related genes were identified using univariate Cox regression, LASSO regression and multivariate Cox regression analyses. The expression and regulatory association of EXOSC4 with NEDD8 and Cullin1 neddylation were validated in clinical samples and AML cell lines using qRT-PCR and Western blotting. CCK-8 assays were performed to evaluate the effects of EXOSC4 overexpression, MLN4924, erastin and Ferrostatin-1 on AML cell viability. A ceRNA regulatory network was constructed based on the key neddylation-related genes. GO and KEGG enrichment analyses showed that differentially expressed neddylation-related genes were mainly enriched in post-translational modification-related biological processes and pathways. Cox regression analyses identified EXOSC4 as a prognostic neddylation-related gene significantly associated with AML prognosis. Validation in clinical samples showed that EXOSC4 and NEDD8 were differentially expressed at both the mRNA and protein levels. In vitro experiments further showed that EXOSC4 expression was positively associated with NEDD8 protein levels and Cullin1 neddylation, suggesting that EXOSC4 may be involved in neddylation-related regulation in AML. Correlation analysis indicated a potential association between neddylation-related dysregulation and ferroptosis-associated pathways. Moreover, CCK-8 assays showed that EXOSC4 overexpression enhanced AML cell viability, whereas MLN4924 suppressed this effect and further enhanced erastin-induced reduction in cell viability, suggesting a potential role of EXOSC4 in ferroptosis-related cellular responses. In conclusion, this study reveals a potential association between neddylation-related dysregulation and ferroptosis-associated pathways in AML. EXOSC4 was identified as a candidate regulatory molecule that may connect neddylation activity with ferroptosis-related cellular responses. These findings provide new insights into the molecular mechanisms of AML and support further investigation of EXOSC4 as a potential therapeutic target.
- 13 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessEXOSC4 as a novel regulator of neddylation in acute myeloid leukemia
Acute myeloid leukaemia (AML) is a common haematological malignancy with an unsatisfactory prognosis despite recent therapeutic advances. Neddylation and ferroptosis have been implicated in the regulation of malignant cell proliferation, survival and therapy response. However, the relationship between neddylation-related dysregulation and ferroptosis-associated pathways in AML remains poorly understood. Transcriptomic data from TCGA-AML and GTEx normal controls were integrated for differential expression and functional enrichment analyses. Prognostic neddylation-related genes were identified using univariate Cox regression, LASSO regression and multivariate Cox regression analyses. The expression and regulatory association of EXOSC4 with NEDD8 and Cullin1 neddylation were validated in clinical samples and AML cell lines using qRT-PCR and Western blotting. CCK-8 assays were performed to evaluate the effects of EXOSC4 overexpression, MLN4924, erastin and Ferrostatin-1 on AML cell viability. A ceRNA regulatory network was constructed based on the key neddylation-related genes. GO and KEGG enrichment analyses showed that differentially expressed neddylation-related genes were mainly enriched in post-translational modification-related biological processes and pathways. Cox regression analyses identified EXOSC4 as a prognostic neddylation-related gene significantly associated with AML prognosis. Validation in clinical samples showed that EXOSC4 and NEDD8 were differentially expressed at both the mRNA and protein levels. In vitro experiments further showed that EXOSC4 expression was positively associated with NEDD8 protein levels and Cullin1 neddylation, suggesting that EXOSC4 may be involved in neddylation-related regulation in AML. Correlation analysis indicated a potential association between neddylation-related dysregulation and ferroptosis-associated pathways. Moreover, CCK-8 assays showed that EXOSC4 overexpression enhanced AML cell viability, whereas MLN4924 suppressed this effect and further enhanced erastin-induced reduction in cell viability, suggesting a potential role of EXOSC4 in ferroptosis-related cellular responses. In conclusion, this study reveals a potential association between neddylation-related dysregulation and ferroptosis-associated pathways in AML. EXOSC4 was identified as a candidate regulatory molecule that may connect neddylation activity with ferroptosis-related cellular responses. These findings provide new insights into the molecular mechanisms of AML and support further investigation of EXOSC4 as a potential therapeutic target.
- Open Access
- 12 January 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (3) , 1401-1414
ANXA1 overexpression promotes B cell acute lymphoblastic leukemia progression and resistance by regulating fatty acid metabolism through PI3K/Akt signaling
Progression and chemoresistance is the main cause of acute lymphoblastic leukemia(ALL) treatment failure. However, its mechanism has not been fully understood. Herein, Annexin A1 (ANXA1) overexpression was found by bioinformatic analysis in B-ALL cells. Clinical specimens were collected to preliminarily explore the role of ANXA1 in B-ALL. It showed that ANXA1 was obviously upregulated in bone marrow samples from B-ALL patients with chemoresistance and correlated with relapse or resistance. Then, we performed cell proliferation and apoptosis assays in CCRF-SB and Nalm6 cells lines in vitro. Overexpression of ANXA1 protected the B-ALL cells from apoptosis induced by dexamethasone and promoted cell cycle progression in vitro. We also found that ANXA1 promoted B-ALL cell proliferation, which correlated with the activated fatty acid metabolism in vitro. Moreover, the content of neutral lipids and the protein expression levels of fatty acid metabolism related ACC1 and FASN proteins were significantly decreased following downregulation of ANXA1. Additionally, high expression of ANXA1 promoted leukemia cell progression by regulating fatty acid metabolism through activating PI3K/AKT signaling pathway. Then in vivo results indicated that downregulation of ANXA1 in B-ALL cells could significantly reduce leukemic cell burden and increase dexamethasone sensitivity. Therefore, ANXA1 was identified as an oncogene in the development and progression of B-ALL and might be a promising biomarker for treating B-ALL.
- 12 January 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (3) , 1401-1414
Open AccessANXA1 overexpression promotes B cell acute lymphoblastic leukemia progression and resistance by regulating fatty acid metabolism through PI3K/Akt signaling
Progression and chemoresistance is the main cause of acute lymphoblastic leukemia(ALL) treatment failure. However, its mechanism has not been fully understood. Herein, Annexin A1 (ANXA1) overexpression was found by bioinformatic analysis in B-ALL cells. Clinical specimens were collected to preliminarily explore the role of ANXA1 in B-ALL. It showed that ANXA1 was obviously upregulated in bone marrow samples from B-ALL patients with chemoresistance and correlated with relapse or resistance. Then, we performed cell proliferation and apoptosis assays in CCRF-SB and Nalm6 cells lines in vitro. Overexpression of ANXA1 protected the B-ALL cells from apoptosis induced by dexamethasone and promoted cell cycle progression in vitro. We also found that ANXA1 promoted B-ALL cell proliferation, which correlated with the activated fatty acid metabolism in vitro. Moreover, the content of neutral lipids and the protein expression levels of fatty acid metabolism related ACC1 and FASN proteins were significantly decreased following downregulation of ANXA1. Additionally, high expression of ANXA1 promoted leukemia cell progression by regulating fatty acid metabolism through activating PI3K/AKT signaling pathway. Then in vivo results indicated that downregulation of ANXA1 in B-ALL cells could significantly reduce leukemic cell burden and increase dexamethasone sensitivity. Therefore, ANXA1 was identified as an oncogene in the development and progression of B-ALL and might be a promising biomarker for treating B-ALL.
- Open Access
- 4 November 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 333 (Pt 2) , 148750
Exosomal microRNA-20b-5p contributes to cytarabine resistance in acute myeloid leukemia via the microtubule-associated serine/threonine kinase-like–phosphatidylinositol 3-kinase–protein kinase B signaling axis
- 4 November 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 333 (Pt 2) , 148750
Open AccessExosomal microRNA-20b-5p contributes to cytarabine resistance in acute myeloid leukemia via the microtubule-associated serine/threonine kinase-like–phosphatidylinositol 3-kinase–protein kinase B signaling axis
- Open Access
- 13 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-16
The ALDH2/PolG2 axis enhances mitochondrial biogenesis via transcriptional regulation of Nrf2 and promotes chemotherapy resistance in acute myeloid leukaemia
Although patients with acute myeloid leukaemia (AML) initially respond to conventional treatments, many patients die from AML progression and relapsed/refractory (RR) disease. Eradicating AML thus remains therapeutically challenging. In this study, we found a strong expression of aldehyde dehydrogenase 2 (ALDH2) and increased mitochondrial biosynthesis in samples from patients with drug-resistant AML, and these changes were strongly associated with poor prognosis and recurrence of AML. We examined the clonogenic capacity, growth and apoptosis of AML cells, as well as mitochondrial DNA expression and reactive oxygen species production. Our results revealed that chemotherapeutic agents triggered the activation of NF-E2-related factor 2 (Nrf2) and promoted high expression of ALDH2, mediating the compensatory activation of mitochondrial respiration and resistance to chemotherapeutic agents in RR AML cells. Nrf2 promoted mitochondrial respiration by activating ALDH2 expression and stabilising the expression of DNA polymerase-gamma2 (PolG2) in mitochondria. Inhibition of the Nrf2-ALDH2/PolG2 pathway reduced AML metabolic fitness and oxidative phosphorylation levels, highlighting the key role of this pathway in promoting cell survival. Nrf2 inhibition reduced the translation of ALDH2, induced a unique mitochondrial stress response and inhibited mitochondrial biosynthesis in AML cells. Importantly, tumours in an in vivo xenograft model were sensitive to combined Nrf2 and ALDH2 inhibition. Given the role of the Nrf2-ALDH2/PolG2 pathway in the progression of AML, inhibition of this pathway may prevent disease relapse/resistance and promote sensitisation to chemotherapy.
- 13 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-16
Open AccessThe ALDH2/PolG2 axis enhances mitochondrial biogenesis via transcriptional regulation of Nrf2 and promotes chemotherapy resistance in acute myeloid leukaemia
Although patients with acute myeloid leukaemia (AML) initially respond to conventional treatments, many patients die from AML progression and relapsed/refractory (RR) disease. Eradicating AML thus remains therapeutically challenging. In this study, we found a strong expression of aldehyde dehydrogenase 2 (ALDH2) and increased mitochondrial biosynthesis in samples from patients with drug-resistant AML, and these changes were strongly associated with poor prognosis and recurrence of AML. We examined the clonogenic capacity, growth and apoptosis of AML cells, as well as mitochondrial DNA expression and reactive oxygen species production. Our results revealed that chemotherapeutic agents triggered the activation of NF-E2-related factor 2 (Nrf2) and promoted high expression of ALDH2, mediating the compensatory activation of mitochondrial respiration and resistance to chemotherapeutic agents in RR AML cells. Nrf2 promoted mitochondrial respiration by activating ALDH2 expression and stabilising the expression of DNA polymerase-gamma2 (PolG2) in mitochondria. Inhibition of the Nrf2-ALDH2/PolG2 pathway reduced AML metabolic fitness and oxidative phosphorylation levels, highlighting the key role of this pathway in promoting cell survival. Nrf2 inhibition reduced the translation of ALDH2, induced a unique mitochondrial stress response and inhibited mitochondrial biosynthesis in AML cells. Importantly, tumours in an in vivo xenograft model were sensitive to combined Nrf2 and ALDH2 inhibition. Given the role of the Nrf2-ALDH2/PolG2 pathway in the progression of AML, inhibition of this pathway may prevent disease relapse/resistance and promote sensitisation to chemotherapy.
- Open Access
- 8 August 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1660169
Correction: Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis
Error in Figure/TableIn the published article, there was an error in [Fig2A, Fig2C, Fig3N, Fig3O, Fig5A, Fig5C] as published. [Image misalignment during image selection of raw data]. The corrected [Fig2A, Fig2C, Fig3N, Fig3O, Fig5A, Fig5C] and its caption appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
- 8 August 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1660169
Open AccessCorrection: Overexpression of Nrf2 in bone marrow mesenchymal stem cells promotes B-cell acute lymphoblastic leukemia cells invasion and extramedullary organ infiltration through stimulation of the SDF-1/CXCR4 axis
Error in Figure/TableIn the published article, there was an error in [Fig2A, Fig2C, Fig3N, Fig3O, Fig5A, Fig5C] as published. [Image misalignment during image selection of raw data]. The corrected [Fig2A, Fig2C, Fig3N, Fig3O, Fig5A, Fig5C] and its caption appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
- 31 July 2025
- Published by Elsevier in Cancer Letters
- Vol. 632, 217963
The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML
- 31 July 2025
- Published by Elsevier in Cancer Letters
- Vol. 632, 217963
The ALDH2-PKC delta-SHMT2 axis regulates cellular metabolic plasticity to promote leukemia stem cells self-renewal and evasion of chemotherapy in AML
- Open Access
- 23 June 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1596947
Cancer associated fibroblasts in tumors: focusing on solid tumors and hematological malignancies
The co evolution of tumor cells and microenvironmental matrix components almost determines the series of processes involved in cancer occurrence and progression. However, many anti-cancer treatments are designed around tumor cells, neglecting the supportive role of stromal cells. Cancer-associated fibroblasts (CAFs), as the main stromal cells in tumor microenvironment, are currently considered as a key component promoting tumorigenesis, development, and regulating the transfer of tumor cells to distant locations through secretion of different growth factors, cytokines, chemokines, and the degradation of extracellular matrix. Therefore, the strategy of targeting both cancer cells and CAFs shows great potential in cancer treatment. In hematological malignancies, the role of CAFs in the progression of tumors has gradually been recently tapped. This review describes the role and functional characteristics of CAFs in tumors, mainly concentrates on the potential role of CAFs in the disease progression of hematological malignancies according to recent findings, and emphasizes the importance of CAFs as a key target to overcome tumor progression and improve treatment efficacy.
- 23 June 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1596947
Open AccessCancer associated fibroblasts in tumors: focusing on solid tumors and hematological malignancies
The co evolution of tumor cells and microenvironmental matrix components almost determines the series of processes involved in cancer occurrence and progression. However, many anti-cancer treatments are designed around tumor cells, neglecting the supportive role of stromal cells. Cancer-associated fibroblasts (CAFs), as the main stromal cells in tumor microenvironment, are currently considered as a key component promoting tumorigenesis, development, and regulating the transfer of tumor cells to distant locations through secretion of different growth factors, cytokines, chemokines, and the degradation of extracellular matrix. Therefore, the strategy of targeting both cancer cells and CAFs shows great potential in cancer treatment. In hematological malignancies, the role of CAFs in the progression of tumors has gradually been recently tapped. This review describes the role and functional characteristics of CAFs in tumors, mainly concentrates on the potential role of CAFs in the disease progression of hematological malignancies according to recent findings, and emphasizes the importance of CAFs as a key target to overcome tumor progression and improve treatment efficacy.
- Open Access
- 13 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1574759
Identification of an Ara-C resistance-related gene risk score and the role of S100A4 in AML via NR6A1-dependent activation and p53 regulation
Indroduction: Ara‐C (cytarabine) resistance remains a significant contributor to the poor clinical outcomes in adult acute myeloid leukemia (AML). However, predicting Ara‐C resistance and developing effective targeted therapies remain challenging.Methods: In this study, we integrated transcriptional data from Ara‐C‐resistant cell lines in the GEO database and the TCGA‐LAML cohort to establish an Ara‐C resistancerelated gene risk score (ARRGRS). Kaplan‐Meier survival analysis revealed that AML patients with high ARRGRS had significantly worse prognosis compared to those with low ARRGRS in both cohorts. Additionally, ARRGRS effectively predicted chemotherapy response in AML patients across both cohorts. To further elucidate the mechanisms underlying Ara‐C resistance, we constructed Ara‐C‐resistant AML cell lines and validated our findings using qPCR, Western blotting, flow cytometry (FCM), and in vivo experiments.Results: We discovered that high expression of S100A4 promotes Ara‐C resistance in AML. Mechanistically, we identified that the transcription factor NR6A1 directly binds to the S100A4 promoter, enhancing its transcriptional activity. Subsequently, S100A4 upregulates p53 expression, thereby promoting AML cell proliferation and resistance to Ara‐C.Discussion: In summary, our comprehensive investigation of the ARRGRS not only deepens the understanding of Ara‐C resistance mechanisms but also provides promising insights for targeting S100A4 to inhibit tumor growth and overcome chemotherapy resistance in AML.
- 13 June 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1574759
Open AccessIdentification of an Ara-C resistance-related gene risk score and the role of S100A4 in AML via NR6A1-dependent activation and p53 regulation
Indroduction: Ara‐C (cytarabine) resistance remains a significant contributor to the poor clinical outcomes in adult acute myeloid leukemia (AML). However, predicting Ara‐C resistance and developing effective targeted therapies remain challenging.Methods: In this study, we integrated transcriptional data from Ara‐C‐resistant cell lines in the GEO database and the TCGA‐LAML cohort to establish an Ara‐C resistancerelated gene risk score (ARRGRS). Kaplan‐Meier survival analysis revealed that AML patients with high ARRGRS had significantly worse prognosis compared to those with low ARRGRS in both cohorts. Additionally, ARRGRS effectively predicted chemotherapy response in AML patients across both cohorts. To further elucidate the mechanisms underlying Ara‐C resistance, we constructed Ara‐C‐resistant AML cell lines and validated our findings using qPCR, Western blotting, flow cytometry (FCM), and in vivo experiments.Results: We discovered that high expression of S100A4 promotes Ara‐C resistance in AML. Mechanistically, we identified that the transcription factor NR6A1 directly binds to the S100A4 promoter, enhancing its transcriptional activity. Subsequently, S100A4 upregulates p53 expression, thereby promoting AML cell proliferation and resistance to Ara‐C.Discussion: In summary, our comprehensive investigation of the ARRGRS not only deepens the understanding of Ara‐C resistance mechanisms but also provides promising insights for targeting S100A4 to inhibit tumor growth and overcome chemotherapy resistance in AML.
- Open Access
- 12 May 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-9
Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial
A novel, highly purified 10% intravenous immunoglobulin (IVIG) formulation was evaluated for both therapeutic efficacy and safety profile in adult patients diagnosed with persistent or chronic primary immune thrombocytopenia (ITP). This phase III, multicenter, open-label, single-arm clinical trial enrolled Chinese adult patients diagnosed with persistent or chronic ITP presenting with baseline platelet counts below 30 × 109/L. Participants received intravenous administration of 10% IVIG at a standardized dosage of 1 g/kg/day for two consecutive days. The primary efficacy endpoint was defined as the proportion of subjects achieving both a platelet count elevation to ≥ 30 × 109/L and a minimum two-fold increase from baseline values within a 7-day post-treatment observation period following the first dose administration. Seventy-two patients were enrolled and sixty patients completed the study. 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved platelet count ≥ 30 × 109/L and experienced a ≥ twofold increase from baseline within 7 days, and 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved complete response (CR) or response (R) within 7 days. 64 patients (88.9%; 95% CI: 79.3, 95.1) achieved platelet count ≥ 50 × 109/L within 7 days with a median time of 3 days. 71 patients completed the ITP bleeding scale assessment after 7 days, showing a decrease of 0.6 ± 1.07 from baseline. A total of 66 patients (91.7%) reported treatment-emergent adverse events (TEAEs) during the study, and 37 patients (51.4%) reported adverse drug reactions (ADRs). The most prevalent ADRs with an incidence exceeding 5% included headache (n = 12, 16.7%), fever (n = 10, 13.9%), decreased white blood cell count (n = 5, 6.9%), and nausea (n = 5, 6.9%). The therapeutic regimen of 10% IVIG administered at a dosage of 1 g/kg/day for two consecutive days demonstrated both favorable safety profiles and clinical efficacy. These robust findings provide substantial evidence supporting the clinical application of this novel 10% IVIG formulation in the management of adult patients with ITP.
- 12 May 2025
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 25 (1) , 1-9
Open AccessEfficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial
A novel, highly purified 10% intravenous immunoglobulin (IVIG) formulation was evaluated for both therapeutic efficacy and safety profile in adult patients diagnosed with persistent or chronic primary immune thrombocytopenia (ITP). This phase III, multicenter, open-label, single-arm clinical trial enrolled Chinese adult patients diagnosed with persistent or chronic ITP presenting with baseline platelet counts below 30 × 109/L. Participants received intravenous administration of 10% IVIG at a standardized dosage of 1 g/kg/day for two consecutive days. The primary efficacy endpoint was defined as the proportion of subjects achieving both a platelet count elevation to ≥ 30 × 109/L and a minimum two-fold increase from baseline values within a 7-day post-treatment observation period following the first dose administration. Seventy-two patients were enrolled and sixty patients completed the study. 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved platelet count ≥ 30 × 109/L and experienced a ≥ twofold increase from baseline within 7 days, and 52 (72.2%; 95% CI: 60.4, 82.1) patients achieved complete response (CR) or response (R) within 7 days. 64 patients (88.9%; 95% CI: 79.3, 95.1) achieved platelet count ≥ 50 × 109/L within 7 days with a median time of 3 days. 71 patients completed the ITP bleeding scale assessment after 7 days, showing a decrease of 0.6 ± 1.07 from baseline. A total of 66 patients (91.7%) reported treatment-emergent adverse events (TEAEs) during the study, and 37 patients (51.4%) reported adverse drug reactions (ADRs). The most prevalent ADRs with an incidence exceeding 5% included headache (n = 12, 16.7%), fever (n = 10, 13.9%), decreased white blood cell count (n = 5, 6.9%), and nausea (n = 5, 6.9%). The therapeutic regimen of 10% IVIG administered at a dosage of 1 g/kg/day for two consecutive days demonstrated both favorable safety profiles and clinical efficacy. These robust findings provide substantial evidence supporting the clinical application of this novel 10% IVIG formulation in the management of adult patients with ITP.